Novo Nordisk (NVO) stopped the trial on the progression of renal impairment for people with Type 2 Diabetes and chronic kidney disease after Ozempic showed success in the study. George Tsilis discusses Ozempic’s impact on two other healthcare stocks Davita (DVA) and Baxter (BAX). Tune in to find out more about the stock market today.
Market On Close
11 Oct 2023
SHARE
Morning Trade Live
07 Mar 2024
Morning Trade Live
03 May 2024
Market On Close
06 Mar 2024
Market On Close
28 Mar 2024
The Watch List
05 Mar 2024
The Watch List
06 Mar 2024